Internalization Cellular Assay
Understanding Cellular Uptake and Trafficking
Internalization assays confirm that a bound compound or biologic is taken up into the cell via endocytic pathways and reaches the intracellular compartments required for activity. Because uptake efficiency directly influences payload delivery, potency, and therapeutic index, these assays are critical for antibody-drug conjugates, targeted radioligands, nucleic acid therapeutics, nanomedicine delivery systems, monoclonal or bispecific antibodies. By quantifying receptor-mediated uptake across these diverse modalities, internalization assays help establish the relationship between target binding, cellular delivery, and downstream phenotypic efficacy.
Quantifying Intracellular Delivery and Receptor Trafficking
Internalization assays provide a direct readout of how efficiently a therapeutic is taken up into target cells after binding, a critical step that governs downstream payload delivery and pharmacological activity.
Application examples:
- Antibody and ADC internalization: Quantify antibody uptake following target binding, a key determinant of payload delivery and potency.
- Receptor internalization and recycling: Characterize receptor trafficking and recycling pathways in GPCRs, receptor tyrosine kinases, and other cell-surface targets.
- Subcellular localization and translocation: Track movement between the plasma membrane, endosomes, cytosol, and nucleus.
- Bystander killing: Assess cytotoxic effects on antigen-negative neighboring cells following payload release from internalized and degraded ADCs.
- Target expression and engagement: Confirm target expression and antibody binding before evaluating internalization.
Internalization Assay Technologies
WuXi Biology and Testing matches detection technology to the modality and throughput required, drawing on a validated set of imaging and flow-based methods, including:
- Flow cytometry: Quantitative internalization and target validation using platforms such as the BD LSRFortessa X20.
- TRF: High-sensitivity, homogeneous detection of internalization and target binding using time-resolved fluorescence.
- Fluorescence and high-content imaging: Visualize uptake and intracellular trafficking at single-cell resolution using multiparametric fluorescence imaging.
- Cell viability and cytotoxicity assays: Confirm the downstream consequences of internalization and payload delivery.
These cellular assays can be complemented by CDX and PDX models to evaluate whether in vitro internalization and trafficking translate into target-dependent uptake and efficacy in vivo.
Therapeutic Modality Coverage
Internalization assays support a broad range of therapeutic modalities in which receptor-mediated uptake influences compound activity, potency, and intracellular delivery, including:
- Conjugates (ADC, PDC, AOCs): Quantify target-dependent uptake and payload delivery.
- Monoclonal and bispecific antibodies: Characterize antibody internalization and receptor trafficking.
- Targeted radioligands: Assess receptor-mediated uptake and intracellular retention.
- Nucleic acid therapeutics (siRNA, ASO, mRNA): Evaluate cellular uptake and endosomal escape efficiency.
- Nanomedicine and delivery systems (LNP, liposomes): Measure receptor-mediated internalization and intracellular trafficking.
- Other targeted modalities (SMDC, PDC, LYTAC): Assess uptake across diverse targeting strategies and disease areas.
By combining internalization assays with downstream viability, cytotoxicity, and imaging readouts, we help establish the relationship between target binding, cellular uptake, and biological activity across diverse therapeutic modalities
Broad Cell-Surface Targets
Internalization assays are applicable to a wide range of cell-surface targets that undergo receptor-mediated uptake, recycling, and trafficking, including:
- Receptor tyrosine kinases (RTKs): EGFR, HER2, c-Met, AXL, and other kinases that undergo ligand- or antibody-induced internalization.
- G protein-coupled receptors (GPCRs): Assess agonist- or antagonist-induced internalization, recycling, and resensitization.
- Immune checkpoints and co-receptors: PD-L1, CTLA-4, CD47, and other targets relevant to immuno-oncology.
- Nutrient and vitamin transporters: Folate receptor, transferrin receptor, and other receptors exploited by SMDCs and nanomedicine.
- Other receptor classes: Integrins, cytokine receptors, and custom targets across diverse disease areas.
These assays enable systematic characterization of target expression, binding, and internalization behavior, providing critical insights for target validation and therapeutic optimization.
Explore Solutions for Your Program
Explore solutions by development phase, drug modality, therapeutic area, or integrated discovery needs.
You May Also Be Interested In
Get a Quote
Ready to plan your next study? Share your program needs with our team for a tailored estimate.
Frequently Asked Questions
An internalization assay measures whether a compound or biologic, once bound to its cell-surface target, is taken up into the cell , a step required for antibody-drug conjugates, targeted radioligands, and many receptor-targeted therapeutics to deliver their intended effect.
Internalization assays are widely used for antibody–drug conjugates, monoclonal and bispecific antibodies, targeted radioligands, nucleic acid therapeutics, nanomedicine delivery systems and other receptor-targeted therapeutics whose activity depends on efficient cellular uptake and intracellular trafficking. These assays can be applied to study internalization across diverse cell-surface targets, including GPCRs, receptor tyrosine kinases, and other receptors involved in therapeutic modulation.
Bystander killing occurs when a cytotoxic payload, released by an antibody-drug conjugate (ADC) inside a target cell, diffuses outward to kill neighboring non-targeted cells. We assess this using cell co-culture, Transwell chamber systems or even in vivo models by quantifying the death rate of the non-targeted cells.
Yes. Receptor-mediated internalization and recycling is relevant to GPCRs, receptor tyrosine kinases, and other cell-surface targets, and can be assessed using our subcellular localization and translocation assay formats.
We use flow cytometry (including platforms such as the BD LSRFortessa X20), TR-FRET/HTRF, and fluorescence/high-content imaging to visualize and quantify uptake and intracellular trafficking, paired with cell viability assays to confirm functional consequence.
Yes. We support CDX and PDX models across multiple ADC-relevant targets (e.g., CLDN18.2, BCMA, Trop-2, CD79b, and Nectin-4), so in vitro internalization findings can be seamlessly translated into in vivo pharmacological efficacy.